3.10Open3.10Pre Close0 Volume180 Open Interest25.00Strike Price0.00Turnover355.85%IV0.79%PremiumDec 20, 2024Expiry Date2.93Intrinsic Value100Multiplier0DDays to Expiry0.18Extrinsic Value100Contract SizeAmericanOptions Type-0.7678Delta0.0899Gamma6.59Leverage Ratio-0.7642Theta-0.0004Rho-5.06Eff Leverage0.0029Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet